Trial NCT04518410
Publication ACTIV-2/A5401 - Chew K, Nat Commun (2022) (published paper)
Primary outcome on the report: 1) development of a Grade 3 or higher treatment emergent adverse event (TEAE) through 28 days; 2) detection (detectable versus undetectable)of SARS-CoV-2 RNA from NP swabs at days 3, 7, 14, 21, and 28; 3) duration of targeted COVID-19-associated symptoms from day 0.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.